Clinical relevance of hyperlipidemia

Area of Science:

• Cardiology
• Preventive Medicine
• Clinical Pharmacology

Background:

• Hyperlipidemia is a major risk factor for cardiovascular disease.
• Clinical trials have investigated the efficacy of lipid-lowering therapies.
• Understanding the mechanisms of lipid-lowering treatment is crucial for cardiovascular event reduction.

Purpose of the Study:

• To review the clinical impact of treating hyperlipidemia.
• To summarize evidence on the effectiveness of lipid-lowering treatments in reducing myocardial infarction.
• To explore the mechanisms by which lipid-lowering therapy impacts atherosclerosis and coronary events.

Main Methods:

• Review of major primary and secondary prevention trials (e.g., Lipid Research Clinics Coronary Primary Prevention Trial, Helsinki Heart Study, Oslo Primary Prevention Trial, Coronary Drug Project).
• Assessment of atherosclerosis progression/regression using invasive and noninvasive methods.
• Evaluation of hemodynamic changes associated with intensive cholesterol-lowering treatments.

Main Results:

• Consistent evidence from primary prevention trials shows intensive, long-term lipid-lowering treatment reduces fatal and nonfatal myocardial infarction.
• Secondary prevention trials confirm these beneficial effects on coronary events.
• Stabilization or regression of arterial lesions is a key mechanism for coronary event reduction.
• Intensive cholesterol-lowering treatments, such as low-density lipoprotein apheresis, may induce beneficial hemodynamic changes.

Conclusions:

• Lipid-lowering treatment is a cornerstone of cardiovascular disease prevention.
• Long-term management of hyperlipidemia effectively reduces myocardial infarction incidence.
• Therapeutic strategies targeting lipid levels contribute to atherosclerosis regression and improved cardiovascular outcomes.